Conventional therapy    (DrugBank: -)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
67多発性嚢胞腎2
222一次性ネフローゼ症候群1

67. 多発性嚢胞腎 [臨床試験数:186,薬物数:196(DrugBank:47),標的遺伝子数:35,標的パスウェイ数:146
Searched query = "Polycystic kidney disease", "PKD", "PCKD", "Polycystic kidney", "ADPKD", "ARPKD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 186 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01223755
(ClinicalTrials.gov)
September 201012/10/2010Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal InsufficiencyEFFECTS OF SIROLIMUS ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND SEVERE RENAL INSUFFICIENCYAutosomal Dominant Polycystic Kidney Disease (ADPKD)Drug: Sirolimus;Drug: conventional therapyMario Negri Institute for Pharmacological ResearchNULLTerminated18 Years80 YearsBoth41Phase 2/Phase 3Italy
2NCT00491517
(ClinicalTrials.gov)
March 200725/6/2007Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and SafetySirolimus Treatment in Patients With ADPKDPolycystic KidneyDrug: Sirolimus;Drug: conventional therapyMario Negri Institute for Pharmacological ResearchNULLCompleted18 Years80 YearsBoth22Phase 2Italy

222. 一次性ネフローゼ症候群 [臨床試験数:234,薬物数:241(DrugBank:78),標的遺伝子数:59,標的パスウェイ数:185
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 234 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02966717
(ClinicalTrials.gov)
August 201630/10/2016Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)The Clinical Study of Rituximab Combined With Mesenchymal Stem Cells in the Treatment of Primary Nephrotic Syndrome (3-4 Stage of Chronic Kidney Disease)Renal Insufficiency, Chronic;Nephrotic SyndromeDrug: Rituximab;Drug: conventional therapy;Drug: Mesenchymal stem cellsZhujiang HospitalNULLActive, not recruiting18 Years65 YearsBoth116Phase 2China